Literature DB >> 28381952

The Treatment of Hepatic Fibrosis: Reversal of the Underlying Disease Process.

Luis Servin-Abad1, Eugene R Schiff1.   

Abstract

Cirrhosis is considered an irreversible end stage of all liver diseases. Current knowledge indicates that fibrosis is part of the liver repair process, which is dynamic. Understanding this repair process will provide better approaches to halt, ameliorate, or reverse fibrosis. The diagnosis of cirrhosis is currently established by liver biopsy and in most advanced cases can be confirmed by imaging. Liver biopsy remains the gold standard but has several limitations: sampling error, size of the biopsy, and both inter- and intra-observer inconsistencies. Hence, many patients can be inaccurately staged for the degree of fibrosis on their initial biopsy, as well as on subsequent re-examination. Although a decrease of 1 stage between consecutive biopsies may be a result of sampling error, the reduction from cirrhosis by at least 2 stages more likely represents a reversal of cirrhosis. There are several cases of reversal of cirrhosis reported in association with different liver diseases. The resolution of fibrosis in the majority of these diseases is related to successful treatment of the underlying etiology (eg, hepatitis B, hepatitis C, iron overload, Wilson disease, alcohol abstinence, metabolic syndrome in fatty liver disease, and decompression of biliary obstruction). The other important feature of reversal of cirrhosis is the successful control of inflammation (eg, autoimmune hepatitis, primary biliary cirrhosis, hepatitis B, C, and D).

Entities:  

Keywords:  Cirrhosis reversal; biliary obstruction; fibrosis regression; hepatitis; nonalcoholic steatohepatitis

Year:  2006        PMID: 28381952      PMCID: PMC5368613     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  50 in total

1.  Therapeutic phlebotomies in idiopathic hemochromatosis.

Authors:  J I BRODY; D McKENZIE; S G KIMBALL
Journal:  Am J Med Sci       Date:  1962-11       Impact factor: 2.378

2.  BIOCHEMICAL STUDIES ON THE CONNECTIVE TISSUE. L. PROLIFERATION AND RE- SORPTION OF THE CONNECTIVE TISSUE IN EXPERIMENTAL LIVER CIRRHOSIS.

Authors:  I ITO
Journal:  Kumamoto Med J       Date:  1964-06-30

Review 3.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

Review 4.  Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis.

Authors:  A Rambaldi; C Gluud
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

5.  Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival.

Authors:  Timothy R Morgan; David G Weiss; Bernard Nemchausky; Eugene R Schiff; Bhupinder Anand; Francis Simon; Jayashri Kidao; Bennet Cecil; Charles L Mendenhall; Douglas Nelson; Charles Lieber; Marcos Pedrosa; Lennox Jeffers; John Bloor; Lawrence Lumeng; Luis Marsano; Craig McClain; Girish Mishra; Brent Myers; Maria Leo; Yelena Ponomarenko; Derek Taylor; Antonio Chedid; Samuel French; Gary Kanel; Natalie Murray; Paul Pinto; Tse-Ling Fong; Mike R Sather
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

6.  Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial.

Authors:  M T Hendrickse; E Rigney; M H Giaffer; I Soomro; D R Triger; J C Underwood; D Gleeson
Journal:  Gastroenterology       Date:  1999-08       Impact factor: 22.682

7.  Treatment of cirrhosis with colchicine. A double-blind randomized trial.

Authors:  D Kershenobich; M Uribe; G I Suárez; J M Mata; R Pérez-Tamayo; M Rojkind
Journal:  Gastroenterology       Date:  1979-09       Impact factor: 22.682

8.  Conversion of micronodular cirrhosis into macronodular cirrhosis.

Authors:  L Fauerholdt; P Schlichting; E Christensen; H Poulsen; N Tygstrup; E Juhl
Journal:  Hepatology       Date:  1983 Nov-Dec       Impact factor: 17.425

9.  Juvenile Wilson disease: histologic and functional studies during penicillamine therapy.

Authors:  R J Grand; G F Vawter
Journal:  J Pediatr       Date:  1975-12       Impact factor: 4.406

10.  Reversal of Indian childhood cirrhosis by D-penicillamine therapy.

Authors:  A M Pradhan; S A Bhave; V V Joshi; A R Bavdekar; A N Pandit; M S Tanner
Journal:  J Pediatr Gastroenterol Nutr       Date:  1995-01       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.